Payer scrutiny, pricing and reimbursement hurdles for new drugs and biologics have increased significantly in the US and globally. This makes it critical to develop strategic plans for reimbursement. In the current environment, product development efforts must start with reimbursement as a central focus. Clinical and economic evidence development and commercialization efforts must be carefully engineered and coordinated among internal functions and across the product’s life cycle to optimize market access and reimbursement potential. “Cookie cutter’ approaches are yielding to customized strategies with sufficient flexibility to weather an evolving reimbursement environment driven by value demonstration and comparative effectiveness.

How should manufacturers retool to navigate reimbursement planning in this brave new world? This seminar will assemble pricing and reimbursement, payer and industry experts in an open forum discussion focused on the following key questions:
* What steps should you take to “reverse engineer” for value demonstration and successful reimbursement?
* How do you distinguish “got to have” versus “nice to know” evidence requirements to develop a reimbursement-focused product development plan?
* How do you balance lessons learned from existing products against future payer requirements to anticipate pitfalls and enhance value differentiation?
* What can you do to avoid risks and seize opportunities precipitated by trends such as comparative effectiveness, personalized medicine and technology convergence?
* What are some examples of existing technologies that effectively navigated payer hurdles based upon solid reimbursement planning? What lessons can be learned from these examples?